Statement of Changes in Beneficial Ownership (4)
July 15 2020 - 4:56PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
MURPHY ANDREW J |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Research |
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/13/2020 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 7/14/2020 | | S(1) | | 264 | D | $630.77 | 44067 | D | |
Common Stock | 7/14/2020 | | S(1) | | 578 | D | $631.32 (2) | 43489 | D | |
Common Stock | 7/14/2020 | | S(1) | | 679 | D | $632.12 (3) | 42810 | D | |
Common Stock | 7/14/2020 | | S(1) | | 95 | D | $633.02 | 42715 | D | |
Common Stock | 7/14/2020 | | S(1) | | 89 | D | $634.18 | 42626 | D | |
Common Stock | 7/14/2020 | | S(1) | | 175 | D | $635.46 (4) | 42451 | D | |
Common Stock | 7/14/2020 | | S(1) | | 182 | D | $637.48 (5) | 42269 | D | |
Common Stock | 7/14/2020 | | S(1) | | 239 | D | $638.96 (6) | 42030 | D | |
Common Stock | 7/14/2020 | | S(1) | | 79 | D | $639.55 | 41951 | D | |
Common Stock | | | | | | | | 4242 | I | By 401(k) Plan |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Non-Qualified Stock Option (right to buy) | $30.63 | 7/13/2020 | | M (1) | | | 13000 | (7) | 12/14/2020 | Common Stock | 13000 | $0.0 | 13736 (8) | D | |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 578 shares of Company stock on July 14, 2020 at prices ranging from $631.07 to $631.43. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. |
(3) | Represents volume-weighted average price of sales of 679 shares of Company stock on July 14, 2020 at prices ranging from $632.04 to $632.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. |
(4) | Represents volume-weighted average price of sales of 175 shares of Company stock on July 14, 2020 at prices ranging from $635.29 to $635.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. |
(5) | Represents volume-weighted average price of sales of 182 shares of Company stock on July 14, 2020 at prices ranging from $637.19 to $637.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. |
(6) | Represents volume-weighted average price of sales of 239 shares of Company stock on July 14, 2020 at prices ranging from $638.87 to $638.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 14, 2020 at each separate price. |
(7) | The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
(8) | Form two of two |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
MURPHY ANDREW J 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 |
|
| EVP Research |
|
Signatures
|
/s/**Andrew Murphy | | 7/14/2020 |
**Signature of Reporting Person | Date |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024